An association between adropin hormone and total testosterone in obese men: a case-control study

Asmaa A Muhammed, Rania M H M Eid, Wafaa Salah Mohammed, Mahmoud R Abdel-Fadeil, Asmaa A Muhammed, Rania M H M Eid, Wafaa Salah Mohammed, Mahmoud R Abdel-Fadeil

Abstract

Background: Obesity is associated with low testosterone levels that could be caused by many mechanisms. Adropin, a peptide hormone, its levels are decreased in obesity and its receptors are expressed in the hypothalamus, the pituitary gland, and the testis. Adropin association to total testosterone in obese men is not detected yet. This study tries to find out possible associations between serum levels of adropin, adiponectin, total testosterone, and lipid profile in obese men.

Methods: Serum levels of adropin, adiponectin, total testosterone, and lipid profile parameters were measured in 43 obese men and 40 age-matched normal-weight men.

Results: Adropin, adiponectin, and testosterone levels were significantly lower in obese men versus normal-weight men. In all participants, positive correlations between adropin, adiponectin, and total testosterone were detected. Adropin is considered a predictor risk factor for testosterone.

Conclusions: This study suggests a possible causal relationship between adropin and total testosterone which needs further investigation.

Trial registration: Clincialtrials.gov NCT03724825 , registered October 30th, 2018.

Keywords: Adiponectin; Adropin; Obesity; Total testosterone.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Correlation between adropin and total testosterone levels in normal-weight and obese men
Fig. 2
Fig. 2
Correlation between adiponectin and total testosterone levels in normal-weight and obese men
Fig. 3
Fig. 3
Correlation between adiponectin and adropin levels in normal-weight and obese men

References

    1. Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288–298. doi: 10.1038/s41574-019-0176-8.
    1. Hruby A, Manson JE, Qi L, Malik VS, Rimm EB, Sun Q, et al. Determinants and consequences of obesity. Am J Public Health. 2016;106(9):1656–1662. doi: 10.2105/AJPH.2016.303326.
    1. Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc. 2015;90(2):224–251. doi: 10.1016/j.mayocp.2014.10.011.
    1. Cunningham GR, Stephens-Shields AJ, Rosen RC, Wang C, Ellenberg SS, Matsumoto AM, et al. Association of sex hormones with sexual function, vitality, and physical function of symptomatic older men with low testosterone levels at baseline in the testosterone trials. J Clin Endocrinol Metab. 2015;100(3):1146–1155. doi: 10.1210/jc.2014-3818.
    1. Fernández-Miró M, Chillarón JJ, Pedro-Botet J. Testosterone deficiency, metabolic syndrome and diabetes mellitus. Medicina Clínica (English Edition) 2016;146(2):69–73. doi: 10.1016/j.medcle.2015.06.002.
    1. Fernandez CJ, Chacko EC, Pappachan JM. Male obesity-related secondary hypogonadism pathophysiology, clinical implications and management. Eur Endocrinol. 2019;15(2):83. doi: 10.17925/EE.2019.15.2.83.
    1. Tsatsanis C, Dermitzaki E, Avgoustinaki P, Malliaraki N, Mytaras V, Margioris ANJH. The impact of adipose tissue-derived factors on the hypothalamic-pituitary-gonadal (HPG) axis. Hormones. 2015;14(4):549–562. doi: 10.14310/horm.2002.1649.
    1. Kelly D, Jones T. Testosterone and obesity. Obes Rev. 2015;16(7):581–606. doi: 10.1111/obr.12282.
    1. Zhao J, Zhai L, Liu Z, Wu S, Xu L. longevity c. Leptin level and oxidative stress contribute to obesity-induced low testosterone in murine testicular tissue. Oxid Med Cell Longev. 2014;2014:1–14.
    1. Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008;8(6):468–481. doi: 10.1016/j.cmet.2008.10.011.
    1. Shahjouei S, Ansari S, Pourmotabbed T, Zand R. Potential roles of adropin in central nervous system: review of current literature. Front Mol Biosci. 2016;3:25. doi: 10.3389/fmolb.2016.00025.
    1. Hoffmeister-Ullerich SA, Süsens U, Schaller HC. research t. The orphan G-protein-coupled receptor GPR19 is expressed predominantly in neuronal cells during mouse embryogenesis. Cell Tissue Res. 2004;318(2):459–463. doi: 10.1007/s00441-004-0948-9.
    1. Thapa D, Stoner MW, Zhang M, Xie B, Manning JR, Guimaraes D, et al. Adropin regulates pyruvate dehydrogenase in cardiac cells via a novel GPCR-MAPK-PDK4 signaling pathway. Redox Biol. 2018;18:25–32. doi: 10.1016/j.redox.2018.06.003.
    1. Gao S, McMillan RP, Jacas J, Zhu Q, Li X, Kumar GK, et al. Regulation of substrate oxidation preferences in muscle by the peptide hormone adropin. Diabetes. 2014;63(10):3242–3252. doi: 10.2337/db14-0388.
    1. Akcilar R, Kocak F, Simsek H, Akcilar A, Bayat Z, Ece E, et al. Antidiabetic and hypolipidemic effects of adropinin streoptozotocin-induced type 2 diabetic rats. Bratislavske lekarske listy. 2016;117(2):100–105.
    1. Chen X, Xue H, Fang W, Chen K, Chen S, Yang W, et al. Adropin protects against liver injury in nonalcoholic steatohepatitis via the Nrf2 mediated antioxidant capacity. Redox Biol. 2019;21:101068. doi: 10.1016/j.redox.2018.101068.
    1. Wong C-M, Wang Y, Lee JTH, Huang Z, Wu D, Xu A, et al. Adropin is a brain membrane-bound protein regulating physical activity via the NB-3/Notch signaling pathway in mice. J Biol Chem. 2014;289(37):25976–25986. doi: 10.1074/jbc.M114.576058.
    1. Zang H, Jiang F, Cheng X, Xu H, Hu X. Serum adropin levels are decreased in Chinese type 2 diabetic patients and negatively correlated with body mass index. Endocrine J. 2018;65(7):685–691. doi: 10.1507/endocrj.EJ18-0060.
    1. Vargas R, Ryder E, Diez-Ewald M, Mosquera J, Durán A, Valero N, et al. Increased C-reactive protein and decreased Interleukin-2 content in serum from obese individuals with or without insulin resistance: Associations with leukocyte count and insulin and adiponectin content. Diabetes Metab Syndr. 2016;10(1):S34–S41. doi: 10.1016/j.dsx.2015.09.007.
    1. Thanakun S, Pornprasertsuk-Damrongsri S. Izumi YJOd. Increased oral inflammation, leukocytes, and leptin, and lower adiponectin in overweight or obesity. Oral Diseases. 2017;23(7):956–965. doi: 10.1111/odi.12679.
    1. Li T, Yang L, Zhao S, Zhang S, Research C Correlation between apolipoprotein M and inflammatory factors in obese patients. Medical Sci Monit. 2018;24:5698. doi: 10.12659/MSM.907744.
    1. Christou G, Kiortsis D. Adiponectin and lipoprotein metabolism. Obesity Rev. 2013;14(12):939–949. doi: 10.1111/obr.12064.
    1. Wen J-P, Lv W-S, Yang J, Nie A-F, Cheng X-B, Yang Y, et al. Globular adiponectin inhibits GnRH secretion from GT1-7 hypothalamic GnRH neurons by induction of hyperpolarization of membrane potential. Biochem Biophys Rescommun. 2008;371(4):756–761. doi: 10.1016/j.bbrc.2008.04.146.
    1. Cheng X-B, Wen J-P, Yang J, Yang Y, Ning G, Li X-Y. GnRH secretion is inhibited by Adiponectin through activation of AMP-activated protein kinase and extracellular signal regulated kinase. Endocrine. 2011;39(1):6–12. doi: 10.1007/s12020-010-9375-8.
    1. Caminos J, Nogueiras R, Gaytán F, Pineda R, Gonzalez C, Barreiro M, et al. Novel expression and direct effects of adiponectin in the rat testis. Endocrinology. 2008;149(7):3390–3402. doi: 10.1210/en.2007-1582.
    1. Faul F, Erdfelder E, Lang A, Buchner AJBRM. A flexible statistical power analysis program for the social, behavioral and biomedical sciences. Behav Res Methods. 2007;39(2):175–191. doi: 10.3758/BF03193146.
    1. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502. doi: 10.1093/clinchem/18.6.499.
    1. Rastrelli G, Carter EL, Ahern T, Finn JD, Antonio L, O'Neill TW, et al. Development of and recovery from secondary hypogonadism in aging men: prospective results from the EMAS. J Clin Endocrinol Metab. 2015;100(8):3172–3182. doi: 10.1210/jc.2015-1571.
    1. Eriksson J, Haring R, Grarup N, Vandenput L, Wallaschofski H, Lorentzen E, et al. Causal relationship between obesity and serum testosterone status in men: a bi-directional mendelian randomization analysis. Plos One. 2017;12(4):e0176277. doi: 10.1371/journal.pone.0176277.
    1. Canguven O, Talib R, El Ansari W, Yassin DJ, Salman M, Al-Ansari AJA. Testosterone therapy has positive effects on anthropometric measures, metabolic syndrome components (obesity, lipidv profile, Diabetes Mellitus control), blood indices, liver enzymes, and prostate health indicators in elderly hypogonadal men. Andrologia. 2017;49(10):e12768. doi: 10.1111/and.12768.
    1. Amjad S, Baig M, Zahid N, Tariq S, Rehman RJA. Association between leptin, obesity, hormonal interplay and male infertility. Andrologia. 2019;51(1):e13147. doi: 10.1111/and.13147.
    1. Hagiuda J, Ishikawa H, Furuuchi T, Hanawa Y, Marumo KJA. Relationship between dyslipidaemia and semen quality and serum sex hormone levels: an infertility study of 167 Japanese patients. Andrologia. 2014;46(2):131–135. doi: 10.1111/and.12057.
    1. Huang G, Yuan M, Zhang J, Li J, Gong D, Li Y, et al. IL-6 mediates differentiation disorder during spermatogenesis in obesity-associated inflammation by affecting the expression of Zfp637 through the SOCS3/STAT3 pathway. Sci Rep. 2016;6(1):1–11. doi: 10.1038/s41598-016-0001-8.
    1. Gao S, Ghoshal S, Zhang L, Stevens JR, McCommis KS, Finck BN, et al. The peptide hormone adropin regulates signal transduction pathways controlling hepatic glucose metabolism in a mouse model of diet-induced obesity. J Biol Chem. 2019;294(36):13366–13377. doi: 10.1074/jbc.RA119.008967.
    1. Lamm S, Chidakel A, Bansal R. Obesity and hypogonadism. Urol Clin. 2016;43(2):239–245. doi: 10.1016/j.ucl.2016.01.005.
    1. Abbasihormozi S, Babapour V. Stress hormone and oxidative stress biomarkers link obesity and diabetes with reduced fertility potential. Cell J (Yakhteh) 2019;21(3):307.
    1. Jasaszwili M, Pruszyńska-Oszmałek E, Wojciechowicz T, Strowski MZ, Nowak KW, Skrzypski M. Adropin Slightly Modulates Lipolysis, Lipogenesis and Expression of Adipokines but Not Glucose Uptake in Rodent Adipocytes. Genes. 2021;12(6):914. doi: 10.3390/genes12060914.
    1. Wang Y, Wang H, Hegde V, Dubuisson O, Gao Z, Dhurandhar NV, et al. Interplay of pro-and anti-inflammatory cytokines to determine lipid accretion in adipocytes. Int J Obes. 2013;37(11):1490–1498. doi: 10.1038/ijo.2013.9.
    1. Pfaehler A, Nanjappa MK, Coleman ES, Mansour M, Wanders D, Plaisance EP, et al. Regulation of adiponectin secretion by soy isoflavones has implication for endocrine function of the testis. Toxicol Lett. 2012;209(1):78–85. doi: 10.1016/j.toxlet.2011.11.027.
    1. Thomas S, Kratzsch D, Schaab M, Scholz M, Grunewald S, Thiery J, et al. Seminal plasma adipokine levels are correlated with functional characteristics of spermatozoa. Fertil Steril. 2013;99(5):1256–63. e3. doi: 10.1016/j.fertnstert.2012.12.022.
    1. Riestra P, Garcia-Anguita A, Ortega L, Garcés C. Relationship of adiponectin with sex hormone levels in adolescents. Horm Res Paediatr. 2013;79(2):83–87. doi: 10.1159/000346898.
    1. Song HJ, Oh S, Quan S, Ryu O-H, Jeong J-Y, Hong K-S, et al. Gender differences in adiponectin levels and body composition in older adults: Hallym aging study. BMC Geriatr. 2014;14(1):1–8. doi: 10.1186/1471-2318-14-8.
    1. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper G. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Investig. 2003;112(1):91–100. doi: 10.1172/JCI200317797.
    1. Frühbeck G, Catalán V, Rodríguez A, Ramírez B, Becerril S, Salvador J, et al. Involvement of the leptin-adiponectin axis in inflammation and oxidative stress in the metabolic syndrome. Sci Rep. 2017;7(1):1–8. doi: 10.1038/s41598-016-0028-x.
    1. Loewen SP, Ferguson AV. Integrative, Physiology C. Adropin acts in the rat Paraventricular nucleus to influence neuronal excitability. Am J Physiol Regul Integr Comp Physiol. 2017;312(4):R511–R5R9. doi: 10.1152/ajpregu.00517.2016.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner